New indications discovered by applying active machine learning and using samples from the company's vast biobank of live-cell tumors specimens "This efficient screening approach on a small, curated cohort of abandoned drugs identified three compounds that warrant further exploration in tumor indications that have never been examined in this way," said Dr. Arlette Uihlein, SVP of Translational Medicine and Drug Discovery and Medical Director at Predictive Oncology. "The work that we have done successfully de ...